Letter to editor – a response to: ‘efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review’
- 30 March 2021
- journal article
- letter
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 22 (7), 939-941
- https://doi.org/10.1080/14656566.2021.1898745
Abstract
Dear Editors,We read with interest the review article by Ritondo et al. on triple therapy in chronic obstructive pulmonary disease (COPD) [1], but disagree with some of the points raised by the aut...Keywords
Funding Information
- National Institute for Health Research
- Manchester Biomedical Research Centre (CTT116855; NCT02164513)
This publication has 13 references indexed in Scilit:
- Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysisRespiratory Research, 2020
- Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trialThe Lancet Respiratory Medicine, 2018
- Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPDThe New England Journal of Medicine, 2018
- Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialThe Lancet, 2018
- AsthmaThe Lancet, 2018
- FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care recordsInternational Journal of Chronic Obstructive Pulmonary Disease, 2017
- Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trialThe Lancet, 2016
- Combined corticosteroid and long-acting beta2 -agonist in one inhaler versus long-acting beta2 -agonists for chronic obstructive pulmonary diseaseEmergencias, 2012
- Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ, 2000